Venous thromboembolism (VTE) in obstetrics - PowerPoint PPT Presentation

1 / 27
About This Presentation
Title:

Venous thromboembolism (VTE) in obstetrics

Description:

... Restriction 3.1 5.8 1.8-5.3 2.1-16 Assisted reproductive therapy 4.3 2.0-9.4 Twins3 2.6 1.1-6.2 APH 1 2.3 1.8-2.8 Post partum haemorrhage ... post partum IV ... – PowerPoint PPT presentation

Number of Views:208
Avg rating:3.0/5.0
Slides: 28
Provided by: HHSC5
Category:

less

Transcript and Presenter's Notes

Title: Venous thromboembolism (VTE) in obstetrics


1
Venous thromboembolism (VTE) in obstetrics
  • Dr. Yasir Katib
  • MBBS, FRCSC, Perinatologist

2
Objectives
  • Incidence
  • Pathogenesis
  • Predisposing factors
  • Prophylaxis
  • Management choices
  • Antepartum
  • Postpartum

3
Incidence
  • Deep venous thrombosis
  • antepartum 0.5-3 per 1000 pregnancies
  • postpartum 0.5-18 per 1000 pregnancies
  • High recurrent risk 7-13
  • pulmonary embolus
  • untreated DVT 24 have PE, 15 mortality
  • treated DVT 5 have PE, 1-2 mortality

4
  • Number of pregnancy deaths from 1982-1992 in
    Canada

5
Postpartum week
Antenatal trimester
Data from CEMACH Maternal deaths enquiries, UK.
Slide courtesy Peter MacCallum
6
Pathogenesis of VTE in pregnancy
Stasis
Hypercoagulation
Vessel wall abnormality
7
Predisposing factors associated with pregnancy
8
Risk factor for VTE OR 95 CI
Previous VTE 1 24.8 17.1-36
Age gt 35 4 1.3 1.0-1.7
BMI gt 30 2 1 5.3 4.4 2.1-13.5 3.4-5.7
Smoking 3 2.7 1.5-4.9
Parity gt3 4 2.4 1.8-3.1
Medical Conditions1 Sickle cell disease, SLE, Heart disease, anaemia, infection, Hyperemesis 2.0 8.7 2.51 2.0-3.2
Immobility 3 7.7 (an) 10.8 (pn) 3.2-19 4-28.8
Pre-eclampsia3 Fetal Growth Restriction 3.1 5.8 1.8-5.3 2.1-16
Assisted reproductive therapy 4.3 2.0-9.4
Twins3 2.6 1.1-6.2
APH 1 2.3 1.8-2.8
Post partum haemorrhage 4.1 2.3-7.3
Caesarean section 4 3.6 3.0-4.3
Varicose veins 2.4 1.04-5.4
Transfusion1 7.6 6.2-9.4
1.James et al 2006 2.Larsen et al 2007
3.Jacobsen et al 2008 4.Lindqvist et al 1999
9
Thrombophilias
  • Congenital
  • resistance to activated protein C (factor V
    leiden)
  • hyperhomocysteinemia (controversial)
  • protein S, C deficiency 2-4 risk, 18-20 risk
    during postpartum
  • antithrombin III deficiency 25-55 risk
  • Acquired
  • antiphospholipid syndrome (APLS) role to cause
    VTE is uncertain

10
Prevalence in population
General population Thrombosis
Factor V leiden 5-9 20-40
Prothrombin G20210A 3 6-15
Protein C def 0.3 1-2
Protein S 0.2 1-2
ATIII def 0.07 lt1
Hyperhomocystin-emia 5 5-10
11
Obstetrical complications of thrombophilia
  • There is growing evidence to suggest that the
    incidence of thrombophilias is also increased in
    women with
  • Late fetal loss (abortions)
  • Gestational hypertension
  • Intrauterine growth restriction
  • IUFD

12
Recommendations for thromboprophylaxis
  • Antepartum
  • all pregnant women who had previous VTE should be
    tested for thrombophilia factors
  • for single episode of prior VTE with transient
    risk factors surveillance (1C)
  • for single episode of idiopathic VTE
    surveillance or UFH or prophylactic LMWH dose
    (1C)
  • for single episode of VTE and thrombophilia
    (except protein S) surveillance (except
    decreased antithrombin) or UFH or prophylactic
    LMWH dose (1C)

13
Recommendations for thromboprophylaxis
  • Women with asymptomatic inherited or acquired
    thrombophilia may be managed with close
    surveillance antenatally.
  • Exceptions are women with antithrombin
    deficiency, those with more than one
    thrombophilic defect (including homozygosity for
    factor V Leiden) or those with additional risk
    factors where advice of a local expert should be
    sought and antenatal prophylaxis considered

14
Antepartum continues
  • known thrombophilia surveillance (except
    decreased antithrombin) or UFH or prophylactic
    LMWH dose (1C)
  • recurrent episodes of VTE adjusted dose of UFH
    or adjusted dose of LMWH (1C)
  • gt 3 moderate risk factors surveillance or UFH or
    prophylactic LMWH dose (1C)

15
Postpartum thromboprophylaxis
  • All women with class 3 obesity (BMI gt 40kg/m2)
    should be considered for thromboprophylaxis with
    LMWH for 7 days after delivery. GPP
  • All women with asymptomatic heritable or acquired
    thrombophilia should be considered for LMWH for
    at least seven days following delivery, even if
    they were not receiving antenatal
    thromboprophylaxis.
  • This should be extended to 6 weeks if there is a
    family history or other risk factors present.
  • Grade C

16
Summary of protocol for thromboprophylaxis in
women with previous VTE and/or thrombophilia These
women require joint specialist management by
obstetricians and experts in haemostasis and
pregnancy
Very High Risk Previous VTE (/- thrombophilia) on long term warfarin Antithrombin deficiency Antiphospholipid syndrome Antenatal high prophylactic or therapeutic dose LMWH and at least six weeks postnatal warfarin.
Antenatal high prophylactic or therapeutic dose LMWH and at least six weeks postnatal warfarin.
High Risk Previous recurrent or unprovoked VTE Previous estrogen (pill / pregnancy) associated VTE
Previous VTE thrombophilia Antenatal and six weeks postnatal prophylactic LMWH
Previous VTE family history of VTE Antenatal and six weeks postnatal prophylactic LMWH
Asymptomatic thrombophilia (combined defects, homozygous FVL or prothrombin gene defect)
Moderate Risk Single previous provoked VTE associated with transient risk factor no longer present without thrombophilia, family history or other risk factors Six weeks postnatal prophylactic LMWH Seven days postnatal LMWH extended to six weeks if family history ve, other risk factors
Asymptomatic thrombophilia (except AT deficiency, combined defects, homozygous FVL or prothrombin gene defect) Six weeks postnatal prophylactic LMWH Seven days postnatal LMWH extended to six weeks if family history ve, other risk factors
17
Prophylactic doses of UFH and LMWH
  • UFH 5000 IU sc bid
  • Prophylactic LMWH
  • Enoxaparin 40 mg sc q24h,
  • Dalteparin 5000 IU sc q24h.
  • Antifactor Xa assay 0.2 and 0.6 U/mL 4 hours
    after the injection

18
IV Heparin
  • inhibits thrombin by activating AT-III, prevents
    conversion of fibrinogen to fibrin
  • need baseline CBC, INR PTT
  • initial 5000 IU bolus, then 1000-1500 IU/hr, INR
    PTT q6hr PTT therapeutic level 1.5-2.5, then
    INR/PTT q24h
  • Advantages
  • doesnt cross placenta
  • not excreted in breast milk

19
IV Heparin
  • rapidly reversible (protamine sulfate
    1mg/100units)
  • no increase in Perinatal mortality or morbidity
    over control
  • Disadvantages
  • bleeding in 4-8
  • osteoporosis (15,000U/d gt 5 months)
  • thrombocytopenia (by day 4)
  • Cost and compliance

20
Low molecular weight heparin
  • Adjusted dose LMWH
  • Enoxaparin 1 mg/kg sc q12h, Dalteparin 200 IU/kg
    sc q24h
  • Advantages
  • possibly less risk of
  • thrombocytopenia
  • osteoporosis
  • more predictable therapeutic effect
  • monitor anti-Xa levels in third trimester

21
Low molecular weight heparin
  • Disadvantages
  • more difficult to reverse
  • drug cost higher but no need for hospitalization

22
Coumadin
  • easily crosses placenta
  • up to 70 fetal complications if in 1st trimester
  • IUGR, chondrodysplasia punctata
  • multiple congenital anomalies
  • 20-30 complication rate in 2nd-3rd trimester
  • Long half life

23
Management during peripartum
  • Therapy throughout pregnancy and 8-12 weeks post
    partum
  • IV Heparin and LMWH should be held once labor is
    established in order to use local anesthesia
  • If therapeutic PTT is required in labor, patient
    should be switched to IV heparin, and local
    anesthesia is contraindicated
  • therapeutic PTT may increase the incidence of
    hematomas but not PPH

24
Management during peripartum
  • Avoid trauma or C/S at delivery
  • midline episiotomy if necessary
  • avoid tears
  • Resume heparin 6 hrs postpartum
  • Start coumadin when oral intake tolerated
  • Avoid OCP, estrogen
  • Consult!

25
Take home message
  • Thromboprophylaxis is recommended for previous
    VTE hx and a known thrombophilia idiopathic VTE,
    recurrent VTE, and more than 3 major risk factors
    for VTE (II B)
  • Diagnosis of VTE is clinical suspicion lab
    tests, never hesitate to order V/Q scan or
    angiography if the result will change management
  • Treatment is long term till postpartum 8-12
    weeks. Considering side effects of different
    drugs, cost, local anesthesia, avoiding
    instrument delivery

26
Take home message
  • Extended use of LMWH
  • Increased number of risk factors
  • Focus on admitted patients
  • Importance of estrogen related prior events
  • Extended duration of LMWH post partum from 3-5
    days to 7 days

27
THANK YOU
Write a Comment
User Comments (0)
About PowerShow.com